Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus HYDROCHLOROTHIAZIDE IRBESARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus HYDROCHLOROTHIAZIDE IRBESARTAN.
FILSPARI vs HYDROCHLOROTHIAZIDE; IRBESARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Irbesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the AT1 receptor, blocking vasoconstriction and aldosterone secretion.
200 mg orally once daily, with or without food.
Hydrochlorothiazide 12.5-25 mg and irbesartan 150-300 mg orally once daily. Maximum dose: hydrochlorothiazide 25 mg/day; irbesartan 300 mg/day.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment); Irbesartan: 11-15 hours (supports once-daily dosing).
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Renal: 70% (irbesartan, unchanged and metabolites); 95% (hydrochlorothiazide, unchanged). Fecal: 30% (irbesartan).
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB